Prostate intraepithelial neoplasia

Summary

Prostate intraepithelial neoplasia (MONDO:0005193) is a disease and 6 clinical trials. Top therapeutic interventions include toremifene, finasteride, and flutamide. A subtype of prostate neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prostate intraepithelial neoplasia
Mondo ID	MONDO:0005193
EFO	EFO:0002621
MeSH	D019048
ICD-10-CM	N42.31
NCIT	C4064
SNOMED CT	254901000
UMLS	C0282612
MedGen	76480
Anatomy (UBERON)	UBERON:0002367
Is cancer (heuristic)	no

Also known as: PIN · pin · pin - prostatic intraepithelial neoplasia · prostate intraepithelial neopl. · prostate intraepithelial neoplasia (pin) · prostatic intraepithelial neoplasia

Disease family

This is a subtype of prostate neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › prostate disorder › prostate neoplasm › prostate intraepithelial neoplasia

Related subtypes (4): prostate neuroendocrine neoplasm, prostate cancer, prostate phyllodes tumor, benign neoplasm of prostate

Subtypes (1): grade III prostatic intraepithelial neoplasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Toremifene	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE3	1
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00106691	PHASE3	COMPLETED	Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
NCT06601205	PHASE2/PHASE3	COMPLETED	Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.
NCT00028353	PHASE2	COMPLETED	A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
NCT00178113	PHASE1	COMPLETED	A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia
NCT00400894	Not specified	UNKNOWN	Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
NCT00535977	Not specified	COMPLETED	Broccoli, Peas and PIN

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TOREMIFENE	4	2
FINASTERIDE	4	1
FLUTAMIDE	4	1
LYCOPENE	3	1
CHEMBL4752424	0	1
CHEMBL4759307	0	1
CHEMBL4777013	0	1